This study evaluated whether nicotinamide (vitamin B3) use is associated with reduced risk of glaucoma, using large-scale commercially available health data.
Reliance on commercially available (claims or EHR) data limits ability to confirm dosage, adherence, or indication for nicotinamide use; residual confounding by unmeasured variables is likely; causal inference cannot be drawn from observational design.
Findings from large-scale real-world data may inform whether nicotinamide supplementation warrants consideration in glaucoma prevention, but clinicians should await confirmatory trial evidence before routinely recommending it.
